StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for IMRX yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-18 | $5.07 | $4.87 | -4.00% | 1.1M |
| 05-19 | $4.91 | $4.89 | -0.41% | 0.7M |
| 05-20 | $4.86 | $5.02 | +3.29% | 0.6M |
| 05-21 | $4.95 | $5.22 | +5.45% | 1.0M |
| 05-22 | $5.99 | $5.39 | -10.02% | 10.2M |
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Annual 2023 2023-12-31 | Q3 2023 2023-09-30 | Q2 2023 2023-06-30 | Q1 2023 2023-03-31 |
|---|---|---|---|---|
Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
Operating Income | $-58.41M | $-42.11M | $-28.18M | $-14.68M |
Net Income | $-53.47M | $-38.39M | $-12.19M | $-13.60M |
EPS (Diluted) | $-1.88 | $-1.36 | $-0.94 | $-0.51 |
Total Assets | $102.58M | $113.88M | $124.90M | $107.70M |
Total Liabilities | $12.01M | $9.86M | $9.79M | $9.91M |
Cash & Equivalents | $59.41M | $68.04M | $104.02M | $77.43M |
Free Cash Flow OCF − CapEx | $-49.31M | $-37.37M | $-25.28M | $-14.45M |
Shares Outstanding | 28.42M | 28.13M | 27.55M | 26.44M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.